Daniel Lin (@danlinmd) 's Twitter Profile
Daniel Lin

@danlinmd

ID: 3047802897

calendar_today20-02-2015 19:53:53

160 Tweet

1,1K Followers

504 Following

Tanya Dorff (@tdorffonc) 's Twitter Profile Photo

Intrigued by reduction in local symptoms with RT in PEACE-1. will be interesting to see how prostatectomy impacts this in #S1802 and of course whether OS could be improved with cytoreductive surgery though RT did not #ASCO23 - please support SWOG trial

Intrigued by reduction in local symptoms with RT in PEACE-1. will be interesting to see how prostatectomy impacts this in #S1802 and of course whether OS could be improved with cytoreductive surgery though RT did not #ASCO23 - please support SWOG trial
Jason Jameson MD (he/him) (@jasonjamesonmd) 's Twitter Profile Photo

In my opinion, an important but often overlooked recommendation is to inform patients BEFORE a prostate biopsy is even done, there is a good chance that if cancer is found, it may be followed with Active Surveillance—it is not a death sentence! #WSAUA23 Western Section AUA

In my opinion, an important but often overlooked recommendation is to inform patients BEFORE a prostate biopsy is even done, there is a good chance that if cancer is found, it may be followed with Active Surveillance—it is not a death sentence!  #WSAUA23 <a href="/auawest/">Western Section AUA</a>
Fred Hutchinson Cancer Center (@fredhutch) 's Twitter Profile Photo

We're pleased to announce the hiring of Lawrence Fong MD as the scientific director of our Immunotherapy Integrated Research Center (IIRC). Starting in July 2024, Fong will lead efforts to scale up Fred Hutch's solid tumor #immunotherapy research. bit.ly/3rRgzFm

Society of Urologic Oncology (@uroonc) 's Twitter Profile Photo

Congratulations to the early-career investigators who were chosen by the Urology Care Foundation (UCF) and the Amer. Urol. Assn. (AUA) to receive funding for the 2023 Research Scholar Award, sponsored by SUO! Full details here: acrobat.adobe.com/link/track?uri…

SWOG Cancer Research Network (@swog) 's Twitter Profile Photo

S2210 is a study for people with #prostatecancer who have an inherited BRCA1 or BRCA2 gene mutation. It tests treatment before surgery using the #chemo drug carboplatin. Learn more at SWOG.org/S2210. Or call 1-800-4-CANCER. Ask about S2210. #pcsm #urology

S2210 is a study for people with #prostatecancer who have an inherited BRCA1 or BRCA2 gene mutation. It tests treatment before surgery using the #chemo drug carboplatin. Learn more at SWOG.org/S2210. Or call 1-800-4-CANCER. Ask about S2210. #pcsm #urology
NCI Cancer Training (@nci_training) 's Twitter Profile Photo

National Cancer Institute is excited to announce & congratulate the 2024 cohort of awardees for the Early-Stage Surgeon Scientist Program (ESSP)! ESSP is designed to train surgeon scientists & retain them in cancer research: go.nih.gov/ckRsJh1 Martha Zeiger MD Lindsay Demblowski Oliver Bogler Nastaran Zahir, PhD

<a href="/theNCI/">National Cancer Institute</a> is excited to announce &amp; congratulate the 2024 cohort of awardees for the Early-Stage Surgeon Scientist Program (ESSP)! ESSP is designed to train surgeon scientists &amp; retain them in cancer research: go.nih.gov/ckRsJh1 <a href="/mzeigermd/">Martha Zeiger MD</a> <a href="/LDemblowski/">Lindsay Demblowski</a> <a href="/NCI_Bogler/">Oliver Bogler</a> <a href="/nas_zahir/">Nastaran Zahir, PhD</a>
UW Urology (@uwurology) 's Twitter Profile Photo

We're thrilled to congratulate Claire de la Calle on securing the NCI Early-Stage Surgeon Scientist Program (ESSP) grant! Your dedication to advancing cancer research is inspiring, and we look forward to seeing the impactful contributions you'll continue to make!

We're thrilled to congratulate <a href="/ClaireDlc/">Claire de la Calle</a> on securing the NCI Early-Stage Surgeon Scientist Program (ESSP) grant! Your dedication to advancing cancer research is inspiring, and we look forward to seeing the impactful contributions you'll continue to make!
Todd 〽️ Morgan, MD (@wandering_gu) 's Twitter Profile Photo

Just out in JAMA: Long-term outcomes of prostate cancer AS in PASS. Since 2008: ➡️2,155 patients with median 7.2 year f/u. ➡️21 patients have developed metastatic disease ➡️3 prostate cancer-related deaths jamanetwork.com/journals/jama/… Track each patient 👇

Just out in <a href="/JAMA_current/">JAMA</a>: Long-term outcomes of prostate cancer AS in PASS. Since 2008:

➡️2,155 patients with median 7.2 year f/u.
➡️21 patients have developed metastatic disease
➡️3 prostate cancer-related deaths

jamanetwork.com/journals/jama/…

Track each patient 👇